{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:04:02Z","timestamp":1790996642090,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T00:00:00Z","timestamp":1434067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Sumitomo Dainippon Pharma Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Previously, we reported 50 mg\/d zonisamide improved wearing\u2010off without increasing dyskinesia in patients with Parkinson's disease (PD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To determine the efficacy of zonisamide for treatment of \u201coff\u201d time in PD patients, we conducted a multicenter, randomized, double\u2010blind, parallel\u2010group, placebo\u2010controlled study in Japan. Patients with PD and wearing\u2010off received placebo for 4 weeks and then were treated for 12 weeks with zonisamide 25 or 50 mg\/d or placebo, in addition to their previous therapy. The primary endpoint was the change from baseline in daily \u201coff\u201d time as determined by patients\u2019 diaries at the final assessment. Secondary endpoints included changes from baseline in the total scores of the Unified Parkinson's Disease Rating Scale Parts I, II, III, and IV, the dyskinesia duration, and PDQ\u201039 score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 422 patients enrolled, 389 (131 for placebo, 130 for zonisamide 25 mg, and 128 for zonisamide 50 mg) were randomized, and 354 (120, 119, and 115, respectively) completed the study. The \u201coff\u201d time significantly reduced by 0.719\u2009\u00b1\u20090.179 h for zonisamide, 50 mg compared with placebo (0.011\u2009\u00b1\u20090.173 h,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005). Although the incidence of somnolence was higher for zonisamide (3.1% for zonisamide 25 mg, 6.3% for zonisamide 50 mg) than for placebo (2.3%), the incidences of the other adverse events, including dyskinesia or hallucination, for both zonisamide treatments were comparable to those for placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study provides evidence that confirms the efficacy of zonisamide 50 mg\/d for reduction in \u201coff\u201d time in PD patients with wearing\u2010off phenomena. \u00a9 2015 International Parkinson and Movement Disorder Society<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mds.26286","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T20:33:07Z","timestamp":1434745987000},"page":"1343-1350","source":"Crossref","is-referenced-by-count":115,"title":["Zonisamide improves wearing\u2010off in Parkinson's disease: A randomized, double\u2010blind study"],"prefix":"10.1002","volume":"30","author":[{"given":"Miho","family":"Murata","sequence":"first","affiliation":[{"name":"Department of Neurology National Center Hospital, National Center of Neurology and Psychiatry Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Neurology Sagamihara National Hospital Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kanazawa","sequence":"additional","affiliation":[{"name":"International University of Health and Welfare Graduate School Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Fukasaka","sequence":"additional","affiliation":[{"name":"Sumitomo Dainippon Pharma Co., Ltd Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kochi","sequence":"additional","affiliation":[{"name":"Sumitomo Dainippon Pharma Co., Ltd Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Shimazu","sequence":"additional","affiliation":[{"name":"Sumitomo Dainippon Pharma Co., Ltd Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Japan Zonisamide on PD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10031"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00188a011"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-0102(01)00298-X"},{"issue":"9","key":"e_1_2_8_5_1","first-page":"S198","article-title":"Randomized, double\u2010blind study of zonisamide with placebo in advanced Parkinson's disease","volume":"19","author":"Murata M","year":"2004","journal-title":"Mov Disord"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000250236.75053.16"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043453180"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(92)90087-A"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(96)80104-X"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00078-X"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2009.11.018"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2009.05.005"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.05.005"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-011-9638-8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-013-1181-2"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21885"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2011.02.017"},{"key":"e_1_2_8_18_1","first-page":"245","article-title":"Research diagnostic criteria for Parkinson's disease","volume":"53","author":"Ward CD","year":"1990","journal-title":"Adv Neurol"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10473"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007730"},{"key":"e_1_2_8_21_1","volume-title":"Linear mixed models for longitudinal data","author":"Verbeke G","year":"2000"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.2307\/2529876"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-100104194"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.4.1060"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7427-3"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21218"},{"key":"e_1_2_8_27_1","unstructured":"Panel on Handling Missing Data in Clinical Trials; National Research Council. The prevention and treatment of missing data in clinical trials. Washington D.C. The National Academies Press 2010. Available from:http:\/\/www.cytel.com\/hs\u2010fs\/hub\/1670\/file\u20102411099288\u2010pdf\/Pdf\/MissingDataNationalAcademyof_Medicine.2010.pdf."},{"key":"e_1_2_8_28_1","unstructured":"Committee for Medicinal Products for Human Use; European Medicines Agency. Guideline on Missing Data in Confirmatory Clinical Trials. London European Medicines Agency Jul 2010.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/09\/WC500096793.pdf."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543400802609797"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26286","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:09:21Z","timestamp":1760969361000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,12]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1002\/mds.26286"],"URL":"https:\/\/doi.org\/10.1002\/mds.26286","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725580073.793509968","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.725580073.793507963","asserted-by":"object"}]},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,12]]}}}